Cohort profile: the Swiss HIV Cohort study (Q46959264)

26 December 2017

title

Cohort profile: the Swiss HIV Cohort study (English)

1 reference

26 December 2017

0 references

Huldrych F Günthard

6

0 references

Swiss HIV Cohort Study

1

object named as

Swiss HIV Cohort Study

1 reference

26 December 2017

9

Sabine Yerly

1 reference

26 December 2017

8

Hansjakob Furrer

1 reference

26 December 2017

Bruno Ledergerber

3

object named as

Bruno Ledergerber

1 reference

26 December 2017

Amalio Telenti

7

object named as

Amalio Telenti

1 reference

26 December 2017

author name string

Franziska Schoeni-Affolter

2

1 reference

26 December 2017

Martin Rickenbach

4

1 reference

26 December 2017

Christoph Rudin

5

1 reference

26 December 2017

Patrick Francioli

10

1 reference

26 December 2017

publication date

30 November 2009

1 reference

26 December 2017

International Journal of Epidemiology

published in

1 reference

26 December 2017

volume

39

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

1179-1189

1 reference

26 December 2017

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

cites work

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Oxalosis and chronic renal failure after intestinal bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Combination antiretroviral therapy and duration of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

High prevalence of peripheral arterial disease in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

HIV rebounds from latently infected cells, rather than from continuing low-level replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Sudden infant death syndrome in infants born to HIV-infected and opiate-using mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Antiretroviral treatment during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

The effect of antiretroviral treatment of different durations in primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Current CD4 Cell Count and the Short‐Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIV‐Infected Children and Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

Prevention of vertical HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FIJE%2FDYP321

21 January 2018

Identifiers

DOI

10.1093/IJE/DYP321

1 reference

26 December 2017

1 reference

26 December 2017